These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8330475)

  • 1. Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids.
    Gurevich VS; Bondarenko BB; Mikhailova IA; Kasennova NI; Popov YuG ; Astashkina ; Le Van Thach TD
    Clin Ter; 1993 Apr; 142(4):329-34. PubMed ID: 8330475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
    Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
    Ghizzoni G; Rusconi C; Faggiano P; Sabatini T; Oneglia C; Gardini A
    Minerva Cardioangiol; 1993 Mar; 41(3):105-9. PubMed ID: 8510811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lovastatin on hypercholesterolemia in chronic renal failure.
    Subang MC; Stewart-Phillips JL; Gagnon RF
    Adv Perit Dial; 1992; 8():381-4. PubMed ID: 1361828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic use of lovastatin in the treatment of hypercholesterolemia.
    Illingworth DR
    Clin Ther; 1994; 16(1):2-26; discussion 1. PubMed ID: 8205598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
    Jover E; Aranda JL; Nogués X; del Palacio A; Rubiés-Prat J
    Med Clin (Barc); 1996 May; 106(20):776-9. PubMed ID: 8801396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of lovastatin (mevacor) on platelet function in hypercholesterolemia in patients with ischemic heart disease].
    Shalaev SV; Safiullina ZM; Zhuravleva TD; Nikitina VI; Baranova TA
    Kardiologiia; 1992 Jun; 32(6):19-21. PubMed ID: 1405285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
    Marta-Moreno J; Echeandia C; Oliveros-Cid A; Figuerola A; Mola S
    Rev Neurol; 1998 Nov; 27(159):827-30. PubMed ID: 9859160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in the rate of cholesterol synthesis in lymphocytes, and blood lipid and lipoprotein levels in patients with ischemic heart disease and hypercholesterolemia during treatment with lovastatin and obsidan].
    Poliakova ED; Ivanova TN; Nikulina SE; Metel'skaia VA; Olfer'ev AM; Shcherbakova IA; Akhmedzhanov NM; Perova NV
    Biull Eksp Biol Med; 1994 Mar; 117(3):248-51. PubMed ID: 8204840
    [No Abstract]   [Full Text] [Related]  

  • 15. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
    Lal SM; Katyal A
    Mo Med; 2002; 99(10):580-4. PubMed ID: 12534147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.